Create Free Account

By creating account you will get access to hot stocks & personalised emails

Mid-Cap

Should you buy Resmed ?

October 31, 2014 | Team Kalkine
Should you buy Resmed ?

Stock of the Day - ResMed Inc. (EXPENSIVE)

ResMed Inc (RMD) is a global leading developer, manufacturer and marketer of medical solutions in the area of sleep-disordered breathing, respiratory care, and cardiorespiratory diseases.

RMD’s FY14 results (ending 30 June, 2014) revealed a 3% increase in net revenues to $1,555.0 million from $1,514.5 million for the year ended June 30, 2013. The key driver of the increase was a surge in unit sales of RMD’s flow generators, masks and accessories (although equipoised by decline in average selling price to a slight extent). The sales were up by 2% in comparison to FY13 after excluding the impact of foreign currency changes.


Strong Financial Track Record in Dollars in Billions, except EPS (Source – Company Reports)

There were positive impacts from international currencies’ movements against the U.S. dollar on RMD’s net revenues. Net revenue in North and Latin America were down by $12.5 million or 1% due to enhanced competitive activity and decreasing average selling prices. On the other hand, net revenue in markets outside North and Latin America were up by $53.0 million or 8%. Net revenue from flow generators totaled $846.7 million (3% rise); and from masks and other accessories totaled $708.3 million (3% increase). Gross profit increased to $989.8 million from $940.7 million of FY13, i.e., up by $49.1 million or 5%, owing to cost savings from manufacturing and supply chain improvements, promising change in product mix, encouraging foreign currency impact. There was an increase in selling, general and administrative expenses owing to an increase in the number of sales and administrative personnel to support growth and other expenses. RMD reported that its combined dividend and buy-back over past 5 years is equivalent to about 103% of free cash flow.
 
The Company confirms to have a healthy historical revenue growth with operational excellence and strong cash flow. Further, it claims to have a robust capital deployment through share repurchases and dividends.

RMD operates in more than 100 countries either directly or with distribution partners. It has an integrated global manufacturing footprint with operations in Australia, France, Singapore, and USA.


Financial Highlights for Q1 2015 (Source – Company Reports)

Based on the Q1 2015 results, the Company aims to improve outcomes and reduce healthcare costs while improving quality-of-life for patients by bringing symptomatic relief. It further intends to provide solutions for preventing chronic disease progression. RMD tries to fulfill above objectives through a broad range of products & solutions which entail connected devices, home sleep testing etc.  


Diversification by Region and Product (Source – Company Reports)

The Company appears to target under penetrated global sleep disordered breathing market while managing new adjacent markets and emerging markets with the help of product innovation.


Horizons of Growth (Source – Company Reports)

The Company has a broad Air Solutions Platform. Further, products like women-specific designed masks (AirSense device), Narval CC™ (oral appliance therapy), and ApneaLink™ Air are some key tools which have helped RMD to continue growth in SDB market segments. 


Air Solutions Platform (Source – Company Reports)

Another category of solutions entail U-Sleep compliance system that improves workflow efficiency. Under RMD’s awareness initiatives, the Company has come-up with “Better Sleep for Women” education and product focused campaign, and also launched S+ sleep monitoring device, which is the world’s first non-contact sleep system available online and in retail stores.


AirFit Mask Family (Source – Company Reports)

With regards to the adjacent growth market, the Company has introduced the Astral life support ventilator, noninvasive ventilation systems, bilevel devices (such as the recent AirCurve™), and Adaptive Servo-Ventilation system.

Under the new business growth, RMD is focusing on clinical studies to demonstrate impact of adaptive servo-ventilation (ASV) on heart failure.


Research in Heart Failure (Source – Company Reports)

Q1 2015 started with a strong performance and increase in sales owing to Astral life support ventilator and other few products such as AirSense; however, it will be too early to comment on the level of returns for FY15 in view of FY14 volatility. EPS growth outlook also does not look favorable. The gross margin guidance for FY15 of 61-63% was provided, which is consistent with the previous quarter guidance. With recovery in Japan, sales under rest of the world segment also bettered. Mask sales were softer with US sales down by 1% and Rest of the World up by 2%. The recent product launches though caught grip but weaker prices led to a downturn. Sales outside the US were comparatively strong.

Also, a few risks that may be of concern include alternate therapies from competitors, price declines, market slowdown, bearing of US competitive bidding, and critical exchange rate movements.

Accordingly, we believe that the stock is EXPENSIVE at the current price of $5.87,  and we would review the same at a later date.


 
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.
Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).
The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.
Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.
The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide.
 
Blue-Chip
An Update on One NASDAQ- Listed Online Services Stock – Alphabet Inc
November 22, 2024Team Kalkine
Blue-Chip
One Internet Services & Infrastructure Stock Near Resistance Levels – SNOW
November 22, 2024Team Kalkine
Small-Cap
One NYSE: Listed Renewable Energy Stock at Resistance Level: Sunnova Energy International Inc
November 22, 2024Team Kalkine
Blue-Chip
One NASDAQ- Listed Renewable Energy Stock at Decent Support Levels– First Solar Inc
November 22, 2024Team Kalkine
Small-Cap
One NASDAQ- Listed Movies & Entertainment ADR Under Radar- iQIYI, Inc
November 22, 2024Team Kalkine

Get In Touch

By submitting your details and clicking on the Register button below, you agree to Kalkine’s Terms and Conditions and agree to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine Pty Ltd or Kalkine Solutions Private Limited on our behalf.You also agree that Kalkine/KSPL can give you its Financial Services Guide by electronic means (including by website link or email). Before accessing our services, please read the Financial Services Guide available here.

Please wait processing your request...

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.